Stifel analyst James Orsborne downgraded Oxford Biomedica to Hold from Buy with a price target of 450 GBp, down from 525 GBp.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OXBDF: